Azadeh Vahdat

Senior Associate, Foreign Qualified Lawyer

Azadeh Vahdat

Azadeh is an Australian qualified IP solicitor in EIP’s litigation team with experience of patent proceedings in the UK High Court and Court of Appeal, and Federal Court of Australia.

Her qualifications include a degree in Biomedical Science and a Juris Doctor from Murdoch University with Distinction, a Graduate Diploma of Legal Practice from the Australian College of Law, and Postgraduate Diploma in Intellectual Property Law and Practice from Oxford University.

Azadeh holds a certificate to practice as a solicitor and barrister in the Supreme Court of Western Australia and High Court of Australia, and an SRA certificate to practise in the UK as a registered foreign lawyer. Azadeh is a member of the Law Society of England and Wales and Western Australia.


  • Optis v Apple [2023] EWCA Civ 438; Optis v Apple [2021] EWHC 3121 (Pat) Acting for Optis in technical trial C for 4G patents in the High Court against Apple upholding the patents as valid and infringed in the Court of Appeal.
  • IP Bridge v Huawei [2021] EWHC 2826 (Pat) Acting for IP Bridge in the above FRAND litigation concerning confidentiality in the High Court, and technical trial B for 3G and 4G patents against Huawei.
  • Conversant v Huawei & ZTE [2020] EWHC 256 Acted for Conversant in the above FRAND litigation concerning the disclosure of comparable licenses in the High Court against Huawei.
  • Apotex v ICOS (No 3) [2018] FCA 1204; Apotex v ICOS [2017] FCA 466 Acting for ICOS (Eli Lilly) in pharmaceutical litigation against Apotex upholding the dosage and particle size patents for Cialis® as valid and infringed in the Federal Court of Australia

Recent work

  • Acting for Alcatel Lucent against Amazon in patent litigation proceedings in the UK.

Published articles

  • May 2024
    EIP Updates, Court of Appeal takes AIM at attempts to show knock-on effect of pragmatic case management (link)
  • August 2023
    EIP Updates, Unnamed inventors can benefit from s.40 employee compensation, but only if you get there in time (link)
  • May 2023
    Oxford University Press, The Doctrine of Equivalents in the UK following Actavis v Lilly’, Part 4, Chapter 33, pp. 527-556, Developments and Directions in Intellectual Property Law: 20 Years of IPKat (link)
  • January 2023
    LSIPR, Why Novartis lost its treatment dispute with Teva (link)
  • January 2023
    EIP Updates, Court of Appeal refuses Arrow declaratory relief for Teva in a stand against forum shopping and jurisdictional imperialism (link)
  • December 2022
    EIP Updates, Novartis overloaded with reasons its iron overload treatment Exjade is obvious and not infringed by Teva (link)
  • August 2022
    Company, Women in Law: A Legal Timeline, in celebration of Women’s Equality Day (link)
  • June 2022
    Update, Patents Court affirms power to grant injunctions for pre-grant patents, but Novartis loses on interim relief and refused permission to appeal by Birss LJ for Gilenya® (link)
  • 2021
    The Trademark Lawyer Annual Magazine, Lucas Film Ltd & Ors v Ainsworth & Anor [2011] – Stormtrooper inventor free to sell helmet, but only in the UK


  • 2021 — 2022
    Postgraduate Diploma in Intellectual Property Law and Practice, Oxford University
  • 2015 — 2016
    Graduate Diploma of Legal Practice , College of Law (Australia)
  • 2011 — 2014
    Juris Doctor, Murdoch University
  • 2007 — 2010
    BSc Biomedical Science, Murdoch University

Career history

  • 2020 — present
    Associate, EIP
  • 2016 — 2019
    Lawyer, Wrays
  • 2014 — 2016
    Analyst, Deloitte

Languages spoken

  • Farsi (fluent)